-
Interim NADIM ADJUVANT Data Suggest Adjuvant Chemo-IO May Reduce Recurrence Risk in Patients Following Complete Resection
-
Final FLAURA2 OS Data Show Osimertinib Plus Chemo Offers Benefit Compared with Monotherapy
-
Potential Impact of GLP1-RAs on TKI-induced Weight Gain in Patients with NSCLC
-
No “Known” Risk Factors: The Health Consequences of Radiation Therapy
-
Discussion Covered Updates, Strategies, and Controversies in Lung Cancer Staging
-
No PFS, OS Benefit Seen in Final Results from PACIFIC-2
-
WCLC Attendees Hear Preview of Proposed Changes for the 9th Edition of the TNM Staging Classification for Thoracic Cancers
-
Treatment of Immunotherapy-Related Dermatologic Toxicities: An Interview with Dr. Mario Lacouture
-
A Holistic Approach to Patient Care
-
Study Shows AI-Based Method Predicts Gene Mutation, Distribution in a More Timely, Accurate, and Economical Way Compared to NGS
Dr. Shan Xiong says the technology achieved robust and superior predictive performance across cancer genes of diverse types and across racial backgrounds.
-
IASLC Recognizes Champions of Lung Cancer Advocacy and Research with STARS Scholar Program
The IASLC’s Supportive Training for Advocates on Research and Science Program Provides Tools, Resources, and Education to Aspiring Patient Research Advocates.
-
In Brief for October 9, 2024
US FDA greenlights subcutaneous atezolizumab, grants Breakthrough Therapy Designation for novel antibody drug conjugate to treat SCLC.
-
IASLC Looks Back at 50 Years of Growth, Collaboration, and Progress in Lung Cancer
A special plenary at WCLC 2024 recognized a half-century of advances in thoracic oncology while reflecting on how far the IASLC has come since its first meeting.
-
Study Shows Patients at Lowest Risk May Benefit from Longer Intervals Between Lung Cancer Screening
Dr. Annette McWilliams says the PanCan nodule management protocol demonstrates potential to streamline lung cancer screening and management processes.
-
Analyzing the CheckMate Trials: How do Clinicians Choose the Winning Strategy for Patients With Resectable NSCLC?
During WCLC 2024, Dr. Patrick Forde presented data from the CheckMate 77T and CheckMate 816 trials that may help guide lung cancer management in the near future.
-
Phase II FLOWERS Trial Unveils Potential New First-Line Therapy Option
Results from the study, presented by Dr. Jin-Ji Yang, suggest that a combination regimen of osimertinib plus savolitinib may be superior to osimertinib alone for EGFR-mutated NSCLC.
-
In Brief for September 25, 2024
Fulzerasib becomes the first KRAS G12C inhibitor approved in China. Encorafenib receives approval from the European Commission. The US FDA grants priority review and breakthrough therapy designation to durvalumab for SCLC.
-
Analysis of Membrane-Bound TROP2 in TROPION-Lung01 Underscores Seminal Advance in Lung Cancer Digital Pathology
A novel computational pathology approach reveals the potential of TROP2 as a predictor of response to anti-TROP2 therapy in NSCLC.
-
FURTHER Study Moves the Needle Farther on Targeted Therapy Directed at Atypical EGFR Mutations in NSCLC
Furmonertinib, an oral, brain-penetrant, mutation-selective EGFR TKI, demonstrates activity in patients with EGFR PACC mutations.